Shivani Mahuvakar
Research Subjects
Shivani Mahuvakar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Adam Carrico
Department of Health Promotion and Disease Prevention, Florida International University , Miami, Florida
1 shared publicationCarlos Moreira
Department of Medicine, University of California , SanFrancisco, California
1 shared publication- David V. Glidden
Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
1 shared publication Emily Arnold
Department of Medicine, University of California , SanFrancisco, California
1 shared publicationEmily J Ross
Department of Health Promotion and Disease Prevention, Florida International University , Miami, Florida
1 shared publicationHideaki Okochi
Department of Medicine, University of California , SanFrancisco, California
1 shared publication
Latest Publications
- Open Access
- 10 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e992-e995
Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT
A remote, motivational interviewing–informed intervention using self-administered point-of-care urine tenofovir testing improved long-term pre-exposure prophylaxis (PrEP) adherence among young US men-who-have-sex-with-men in a pilot randomized trial. Participants increased hair tenofovir levels by 1–2 tablets weekly, with high feasibility and acceptability, supporting further implementation.
- 10 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e992-e995
Open AccessPoint-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT
A remote, motivational interviewing–informed intervention using self-administered point-of-care urine tenofovir testing improved long-term pre-exposure prophylaxis (PrEP) adherence among young US men-who-have-sex-with-men in a pilot randomized trial. Participants increased hair tenofovir levels by 1–2 tablets weekly, with high feasibility and acceptability, supporting further implementation.